These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30575597)

  • 1. Genetic advances in gout: potential applications in clinical practice.
    Tai V; Merriman TR; Dalbeth N
    Curr Opin Rheumatol; 2019 Mar; 31(2):144-151. PubMed ID: 30575597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The genetics of gout: towards personalised medicine?
    Dalbeth N; Stamp LK; Merriman TR
    BMC Med; 2017 May; 15(1):108. PubMed ID: 28566086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic considerations in the treatment of gout.
    Roberts RL; Stamp LK
    Pharmacogenomics; 2015; 16(6):619-29. PubMed ID: 25876828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
    Yu KH; Lai JH; Hsu PN; Chen DY; Chen CJ; Lin HY
    Scand J Rheumatol; 2016 Jul; 45(4):304-11. PubMed ID: 26771445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genetics of hyperuricaemia and gout.
    Reginato AM; Mount DB; Yang I; Choi HK
    Nat Rev Rheumatol; 2012 Oct; 8(10):610-21. PubMed ID: 22945592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
    Torres RJ; Puig JG
    Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout.
    Roberts RL; Wallace MC; Phipps-Green AJ; Topless R; Drake JM; Tan P; Dalbeth N; Merriman TR; Stamp LK
    Pharmacogenomics J; 2017 Mar; 17(2):201-203. PubMed ID: 26810134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
    Graham GG; Stocker SL; Kannangara DRW; Day RO
    Curr Rheumatol Rep; 2018 Jun; 20(8):47. PubMed ID: 29931553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.
    Ke CH; Chung WH; Wen YH; Huang YB; Chuang HY; Tain YL; Wang YL; Wu CC; Hsu CN
    J Rheumatol; 2017 Jun; 44(6):835-843. PubMed ID: 28365572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China.
    Cheng H; Yan D; Zuo X; Liu J; Liu W; Zhang Y
    Pharmacogenet Genomics; 2018 May; 28(5):117-124. PubMed ID: 29642234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?
    Teng GG; Tan-Koi WC; Dong D; Sung C
    Pharmacogenomics; 2020 Mar; 21(4):279-291. PubMed ID: 32180492
    [No Abstract]   [Full Text] [Related]  

  • 12. Current and future therapies for gout.
    Pascart T; Richette P
    Expert Opin Pharmacother; 2017 Aug; 18(12):1201-1211. PubMed ID: 28689430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient].
    Sun Y; Li L; Zhou TY; Lu W
    Yao Xue Xue Bao; 2014 Dec; 49(12):1674-83. PubMed ID: 25920196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
    Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
    Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major unanswered questions in the clinical gout field.
    Stamp LK
    Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
    Hill EM; Sky K; Sit M; Collamer A; Higgs J
    J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with allopurinol decreases the number of acute gout attacks despite persistently elevated serum uric acid levels.
    Beutler AM; Rull M; Schlesinger N; Baker DG; Hoffman BI; Schumacher HR
    Clin Exp Rheumatol; 2001; 19(5):595. PubMed ID: 11579724
    [No Abstract]   [Full Text] [Related]  

  • 18. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
    Baumgartner S; Yeh LT; Shen Z; Kerr B; Manhard K; Quart B
    J Clin Pharmacol; 2018 Sep; 58(9):1164-1170. PubMed ID: 29733441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on the genetics of hyperuricaemia and gout.
    Major TJ; Dalbeth N; Stahl EA; Merriman TR
    Nat Rev Rheumatol; 2018 Jun; 14(6):341-353. PubMed ID: 29740155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.